Shire expected to earn $50 million for its Gaucher drug
스크롤 이동 상태바
Shire expected to earn $50 million for its Gaucher drug
기자명
메디칼라이터팀
입력 2009.09.13 00:00
수정 2009.09.13 10:24
댓글 0
Shire"s Gaucher disease drug velaglucerase alfa, which was rushed to market a year earlier because of Genzyme Corp.’s manufacturing disruption, could take a 15 percent of the $1.1 billion market by 2012 as well as earning $50 million in 2010. Shire has submitted a safety plan to the FDA allowing the drug to be available whilst Genzyme continues to make its new supply.